CNBC July 24, 2024
Annika Kim Constantino

Key Points

– Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval.

– The hemophilia A treatment could become the company’s second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.

– Pfizer is among several drugmakers to invest in the rapidly growing field of gene and cell therapies — one-time, high-cost treatments that target a patient’s genetic source or cell to cure or significantly alter the course of a disease.

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article